ISA

Attralus Presents New Data on Its Pan-Amyloid Therapeutic and Diagnostic Candidates at the XIX International Symposium on Amyloidosis (ISA)

Retrieved on: 
Giovedì, Maggio 30, 2024
Quality, Heart, AT-02, Lung, Marker, Immunotherapy, SUV, Cardiac amyloidosis, Amyloid cardiomyopathy, Liver, Detection, University, Diagnosis, Map, ISA, Disease, Serum, Assistant, Kidney, Phagocytosis, ATTR, Poster, Abstract, Mortality, AA, Hypertrophic cardiomyopathy, Quality of life, Amyloid, Spleen, Medical imaging

AT-01, the first pan-amyloid diagnostic imaging agent, demonstrated high levels of sensitivity and specificity for detection of cardiac amyloid.

Key Points: 
  • AT-01, the first pan-amyloid diagnostic imaging agent, demonstrated high levels of sensitivity and specificity for detection of cardiac amyloid.
  • The company also announced two presentations from AT-02, including highly encouraging preclinical data for AT-02, the company’s lead pan-amyloid removal therapeutic candidate in an oral presentation.
  • In total, 16 abstracts were presented related to Attralus’ pan-amyloid pipeline including three oral and 13 poster presentations at the XIX International Symposium on Amyloidosis (ISA) held in Rochester, MN.
  • 124I-evuzamitide PET/MRI provided comprehensive diagnostic evaluation and organ survey of patients suspected to have or diagnosed with systemic amyloidosis.

Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Retrieved on: 
Mercoledì, Maggio 29, 2024
ACT, Patient, Prognosis, Survival, Amyloidosis, American Heart Association, Month, Risk, Food, ACC, NDA, European Medicines Agency, Calendar, University, ISA, Safety, Serum, ESC, PDUFA, AHA, Congress, Death, Cancer, Biomarker, Cox, Columbia University, Mortality, CVH, MAA, Vancouver General Hospital, American College, Webcast, CVM, Quality of life, TTR, Pharmaceutical industry

ATTRibute-CM was designed to study the efficacy and safety of acoramidis, an investigational, next-generation, orally administered, highly potent, small molecule stabilizer of TTR.

Key Points: 
  • ATTRibute-CM was designed to study the efficacy and safety of acoramidis, an investigational, next-generation, orally administered, highly potent, small molecule stabilizer of TTR.
  • BridgeBio will host an investor call on Wednesday, May 29th at 5:30 pm ET to discuss these results.
  • “The data presented at ISA confirm that improved stabilization as reflected in higher serum TTR levels is directly correlated with improved clinical outcomes.
  • Prior analyses from ATTRibute-CM demonstrated that the near-complete stabilization by acoramidis rapidly and durably increased serum TTR levels.

Director/PDMR Shareholding

Retrieved on: 
Mercoledì, Maggio 29, 2024
Shell plc, Individual savings account, ISA, Shell, Person, PCA, Bookbinding

Shell plc (the “Company”) announces that on May 23, 2024:

Key Points: 
  • Shell plc (the “Company”) announces that on May 23, 2024:
    a)   Philippa Bounds, a Person Discharging Managerial Responsibilities (“PDMR”), has, in order to effect a "Bed and ISA” transaction, sold 8,961 shares of €0.07 each in the Company (“Shares”) and immediately repurchased 8,961 shares into her Individual Savings Account (“ISA”); and, separately:
    b)   James Bounds, a person closely associated (“PCA”) with Philippa Bounds, has purchased 312 Shares into his ISA; and
    c)   Alfred Bounds, a PCA with Philippa Bounds, has purchased 312 Shares into his ISA; and
    d)   George Bounds, a PCA with Philippa Bounds, has purchased 312 Shares into his ISA.
  • Further details regarding these transactions are shown in the PDMR notifications below.

SEALSQ RISC-V Chips Adoption is Predicted to Get AI Boost Making it a Viable Competitor to Traditional GPUs

Retrieved on: 
Venerdì, Maggio 24, 2024
Semiconductor, Running, App Store (iOS/iPadOS), Work, Health, Machine learning, PKI, ISA, City, Engineering, 2.0, Internet of things, Central processing unit, Growth, Graphics processing unit, Research, MCU, TPM, LAES, Architecture, Original equipment manufacturer, Tablet, Communication, Post-quantum cryptography, Near-field communication, Library, Criterion, Common Criteria, GPU, Video game

SEALSQ is recognized as a leading innovator in the development of high-performance RISC-V AI processors and secure microcontrollers.

Key Points: 
  • SEALSQ is recognized as a leading innovator in the development of high-performance RISC-V AI processors and secure microcontrollers.
  • RISC-V, an open-source instruction set architecture (ISA), is poised to challenge the dominance of powerful GPUs in the AI landscape.
  • By designing RISC-V processors with specific AI accelerators, they can achieve higher performance-per-watt compared to general-purpose GPUs, making them suitable for energy-sensitive environments.
  • This robust software ecosystem helps developers efficiently implement AI solutions on RISC-V processors, making it a viable competitor to traditional GPUs.

BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting

Retrieved on: 
Venerdì, Maggio 24, 2024
ACT, Attribute, Patient, Survival, University College London, CMR, Risk, Calendar, Doctor of Philosophy, ISA, ESC, Serum, Hospital, Medical school, Cancer, Biomarker, Columbia University, Mortality, Webcast, KCCQ, Quality of life, TTR, Lobster

PALO ALTO, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that 12 oral and moderated poster presentations will be shared at the 2024 International Symposium on Amyloidosis (ISA), taking place in Rochester, Minnesota on May 26 - 30, 2024.

Key Points: 
  • - BridgeBio to host investor call on Wednesday, May 29, 2024 at 5:30 pm ET, with presentations from Mathew Maurer, M.D.
  • BridgeBio will also host an investor call on May 29, 2024, at 5:30 pm ET to discuss the recent analyses and positive data from the ATTRibute-CM Phase 3 trial and emerging real-world evidence in ATTR-CM.
  • To access the oral presentations and moderated poster presentations following the Company’s participation at the 2024 ISA, please visit investor.bridgebio.com/presentations .
  • A link to the webcast may be accessed from the event calendar page of BridgeBio’s website at https://investor.bridgebio.com/ .

VEON Receives Nasdaq Notice on Delayed Filing, Confirms Ongoing Effort to Address Auditor Appointment

Retrieved on: 
Mercoledì, Maggio 22, 2024
International Standards on Auditing, VEON, PwC, Calendar, ISA, Bank statement, PCAOB, Annual report, International standard, Euronext Amsterdam

Nasdaq has given the Company until July 19, 2024 to submit its plan to regain compliance under Nasdaq Listing Rule 5250(c)(1) and the Company expects to submit its plan by such date.

Key Points: 
  • Nasdaq has given the Company until July 19, 2024 to submit its plan to regain compliance under Nasdaq Listing Rule 5250(c)(1) and the Company expects to submit its plan by such date.
  • Following submission of the Company's plan to Nasdaq, Nasdaq may grant the Company an exception of up to 180 calendar days, or until November 11, 2024,  to regain compliance.
  • The notification has no immediate effect on the continued listing status of VEON’s American Depositary Shares (“ADSs”) on Nasdaq and its ADSs will continue to trade on The Nasdaq Capital Market.
  • Furthermore, VEON’s business operations are not affected by the receipt of the notification.

AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)

Retrieved on: 
Giovedì, Maggio 23, 2024
Biotechnology, FDA, Pharmaceutical, Health, Patient, RWE, Bortezomib, Science, Heart failure, Prevalence, Diagnosis, ISA, Disease, Epidemiology, EMR, Senior, Death, Alexion, Ionis, Macrophage, Incidence, Polyneuropathy, Cardiomyopathy, Phagocytosis, ATTR, Poster, Inborn errors of metabolism, Outline, AstraZeneca, Daratumumab, Amyloid, Pharmaceutical industry

AstraZeneca and Alexion, AstraZeneca Rare Disease, will showcase 14 studies, including real-world evidence (RWE), from their portfolio and pipeline of investigational amyloidosis therapies at the International Symposium on Amyloidosis (ISA), in Rochester, MN from May 26–30, 2024.

Key Points: 
  • AstraZeneca and Alexion, AstraZeneca Rare Disease, will showcase 14 studies, including real-world evidence (RWE), from their portfolio and pipeline of investigational amyloidosis therapies at the International Symposium on Amyloidosis (ISA), in Rochester, MN from May 26–30, 2024.
  • Sarah Walters, Vice President, US Cardiovascular, Renal & Metabolic Diseases, AstraZeneca, said: “AstraZeneca is dedicated to advancing the science and improving the lives of patients that are impacted by this devastating disease.
  • A retrospective chart analysis from the US EMR TriNetX database will report outcomes in AL amyloidosis patients with renal involvement receiving bortezomib or daratumumab.
  • A comprehensive list of AstraZeneca key abstracts to be presented at the 2024 International Symposium on Amyloidosis includes7:

Frontgrade Gaisler Leads the Way in RISC-V Processor Development for Space Applications

Retrieved on: 
Lunedì, Maggio 13, 2024
Semiconductor, Defense, Satellite, Technology, Aerospace, Manufacturing, Other Defense, Radiation, Australian Space Agency, ESA, Field-programmable gate array, European Space Agency, Ecosystem, ISA, IP, Architecture, SPARC, Multimedia, SOC, Video game

Under a contract with the European Space Agency (ESA), Frontgrade Gaisler is designing a new RISC-V processor tailored to meet the requirements of microcontrollers for the space industry.

Key Points: 
  • Under a contract with the European Space Agency (ESA), Frontgrade Gaisler is designing a new RISC-V processor tailored to meet the requirements of microcontrollers for the space industry.
  • View the full release here: https://www.businesswire.com/news/home/20240513076795/en/
    Under a contract with the European Space Agency (ESA), Frontgrade Gaisler is designing a new RISC-V processor tailored to meet the requirements of microcontrollers for the space industry.
  • "Frontgrade Gaisler has decades of experience supplying the space industry with products that implement open standards, and now we’re applying our proven know-how to bring RISC-V advancements to the space industry," said Sandi Habinc, General Manager at Frontgrade Gaisler.
  • Frontgrade Gaisler is a leading provider of radiation-hardened microprocessors and IP cores for critical applications, particularly in the space industry.

Hargrove Controls & Automation's Karen Griffin Receives CSIA's 2024 Charlie Bergman 'Remember Me' Award

Retrieved on: 
Martedì, Maggio 14, 2024
Emerald, ECC, Learning, Grandparent, Organization, Construction, Control, International Society, ISA, Engineering, Life, Conference, P.E, Philosophy, Growth, Control System, Sage Group, Griffin, EPC, Culture, Volunteering, College of Engineering (KNUST), Knowledge, Management

MOBILE, Ala., May 14, 2024 /PRNewswire-PRWeb/ -- Hargrove Controls & Automation, a leading industrial automation system integrator and a subsidiary of global EPC firm Hargrove Engineers & Constructors, announced today that Vice President Karen Griffin, P.E. was presented the distinguished 2024 Charlie Bergman 'Remember Me' Award at the Control System Integrators Association (CSIA) Conference in Dallas, TX.

Key Points: 
  • Karen Griffin, P.E., Vice President of Hargrove Controls & Automation receives the distinguished Charlie Bergman 'Remember Me' Award at the 2024 Control System Integrators Association Conference.
  • was presented the distinguished 2024 Charlie Bergman 'Remember Me' Award at the Control System Integrators Association (CSIA) Conference in Dallas, TX.
  • Of the five award categories , the Charlie Bergman 'Remember Me' Award is considered to be the most exemplary of the organization.
  • "If there is anyone who embodies the principles of Charlie Bergman, it's Karen," said Ralph Hargrove, CEO and President of Hargrove.

New Automotive Grade Linux Platform Release Adds Cloud-Native Functionality, RISC-V Architecture and Flutter-Based Applications

Retrieved on: 
Giovedì, Maggio 9, 2024
Cloud, Continuity, Ecosystem, UI, Amazon Web Services, SDV, Toyota, SOC, Amazon Elastic Compute Cloud, Software, Business development, Customer experience, Traction, Research, QEMU, Amazon, UCB, SVP, Socs, Continuous integration, AGL, Flutter, Écu, ISA, Automotive Grade Linux, Running, CES, API, HVAC, AWS, SAN, Architecture, SiFive, Video game

SAN FRANCISCO, May 9, 2024 /PRNewswire/ -- Automotive Grade Linux (AGL), a collaborative cross-industry effort developing an open source platform for all Software-Defined Vehicles (SDVs), has announced the latest code release of the AGL platform, UCB 17.0 or "Quirky Quillback."

Key Points: 
  • "Established brands and fast-growing startups within the automotive industry are all embracing SDV technologies," said Stefano Marzani, worldwide technology leader, SDV, AWS.
  • The latest release also includes a vehicle-to-cloud demo application that can be used to access KUKSA.val and CAN signals remotely.
  • Quirky Quillback also includes Toyota's automotive embedded version of Flutter , an open source app and UI development toolkit, that was designed specifically for automotive applications.
  • "We are excited that Automotive Grade Linux is now the home for automotive embedded Flutter, which we believe will become the de facto standard for developing in-vehicle applications."